LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
LARIMAR THERAPEUTICS, INC. (LRMR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.64 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 489.75K shares, a 129.18% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.15M shares, a 0.74% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 73.00K shares, a 39.12% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 213.70K shares, a 44.07% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.24M shares, a 27.87% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.75M shares, a 99.01% increase from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 878.45K shares, a 40.16% increase from fiscal 2021.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 626.75K shares, a 53.78% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 489.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 2.64M shares 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | 2.15M shares 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | 73.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 286.70K shares derived: sum of 2 quarters · filed 2025-11-05 | 2.42M shares 10-Q · filed 2025-11-05 | 2.57M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 213.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 2.34M shares 10-Q · filed 2025-08-14 | 2.50M shares derived: sum of 3 quarters · filed 2025-08-14 | 2.62M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 2.13M shares 10-Q · filed 2025-04-30 | 2.28M shares derived: sum of 2 quarters · filed 2025-04-30 | 2.40M shares derived: sum of 3 quarters · filed 2025-04-30 | 2.79M shares derived: sum of 4 quarters · filed 2025-04-30 |
| 2024-12-31 | 153.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 272.90K shares derived: sum of 2 quarters · filed 2025-03-24 | 655.00K shares derived: sum of 3 quarters · filed 2025-03-24 | 2.24M shares 10-K · filed 2025-03-24 |
| 2024-09-30 | 119.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | 502.00K shares derived: sum of 2 quarters · filed 2024-10-30 | 2.08M shares 10-Q · filed 2024-10-30 | 2.14M shares derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-06-30 | 382.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.96M shares 10-Q · filed 2024-08-08 | 2.02M shares derived: sum of 3 quarters · filed 2024-08-08 | 2.24M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.58M shares 10-Q · filed 2024-05-09 | 1.64M shares derived: sum of 2 quarters · filed 2024-05-09 | 1.86M shares derived: sum of 3 quarters · filed 2024-05-09 | 2.04M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 59.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 275.00K shares derived: sum of 2 quarters · filed 2024-03-14 | 460.20K shares derived: sum of 3 quarters · filed 2024-03-14 | 1.75M shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 215.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 400.40K shares derived: sum of 2 quarters · filed 2023-11-14 | 1.69M shares 10-Q · filed 2023-11-14 | 1.70M shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 185.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.47M shares 10-Q · filed 2023-08-10 | 1.48M shares derived: sum of 3 quarters · filed 2023-08-10 | 1.50M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 1.29M shares 10-Q · filed 2023-05-15 | 1.30M shares derived: sum of 2 quarters · filed 2023-05-15 | 1.31M shares derived: sum of 3 quarters · filed 2023-05-15 | 1.57M shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 26.00K shares derived: sum of 2 quarters · filed 2023-03-14 | 277.50K shares derived: sum of 3 quarters · filed 2023-03-14 | 878.45K shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 16.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 267.50K shares derived: sum of 2 quarters · filed 2022-11-10 | 868.45K shares 10-Q · filed 2022-11-10 | 878.05K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 251.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 852.45K shares 10-Q · filed 2022-08-11 | 862.05K shares derived: sum of 3 quarters · filed 2022-08-11 | 876.15K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 600.95K shares 10-Q · filed 2022-05-12 | 610.55K shares derived: sum of 2 quarters · filed 2022-05-12 | 624.65K shares derived: sum of 3 quarters · filed 2022-05-12 | 825.15K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 9.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | 23.70K shares derived: sum of 2 quarters · filed 2022-03-25 | 224.20K shares derived: sum of 3 quarters · filed 2022-03-25 | 626.75K shares 10-K · filed 2022-03-25 |
| 2021-09-30 | 14.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 214.60K shares derived: sum of 2 quarters · filed 2021-11-12 | 617.15K shares 10-Q · filed 2021-11-12 | 671.25K shares derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | 200.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 603.05K shares 10-Q · filed 2021-08-12 | 657.15K shares derived: sum of 3 quarters · filed 2021-08-12 | 1.90M shares derived: sum of 4 quarters · filed 2021-08-12 |
| 2021-03-31 | 402.55K shares 10-Q · filed 2021-05-10 | 456.65K shares derived: sum of 2 quarters · filed 2021-05-10 | 1.70M shares derived: sum of 3 quarters · filed 2021-05-10 | |
| 2020-12-31 | 54.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | 1.30M shares derived: sum of 2 quarters · filed 2021-03-04 | 1.36M shares 10-K · filed 2021-03-04 | |
| 2020-09-30 | 1.24M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 1.30M shares 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | 60.48K shares 10-Q · filed 2020-08-14 | |||
| 2019-09-30 | 2.28M shares 10-Q · filed 2019-11-06 | |||
| 2016-12-31 | 1.53M shares 10-K · filed 2017-03-10 | |||
| 2015-12-31 | 24.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | 992.50K shares 10-K · filed 2017-03-10 | ||
| 2015-09-30 | 968.30K shares 10-Q · filed 2015-11-13 | |||
| 2014-12-31 | 698.64K shares 10-K · filed 2016-03-15 | |||
| 2014-09-30 | 0.00 shares 10-Q · filed 2014-11-13 | 326.54K shares derived: sum of 2 quarters · filed 2014-11-13 | ||
| 2014-06-30 | 326.54K shares 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |